DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: VIOXX

Summary for Tradename: VIOXX

Patents:4
Applicants:1
NDAs:2
drug
patent expirations by year for
 VIOXX

Clinical Trials for: VIOXX

Study of Vioxx and Radiation Therapy for Brainstem Glioma
Status: Terminated Condition: Glioma; Brain Neoplasms

A Four-Week Study Comparing Acetaminophen Extended Release and Rofecoxib in the Treatment of Osteoarthritis of the Knee
Status: Completed Condition: Osteoarthritis of the Knee

CI(R)CA : Coumadin Interaction With Rofecoxib, Celecoxib and Acetaminophen
Status: Completed Condition: Antiphospholipid Antibody Syndrome

A Study to Evaluate the Effect of MK0966 (Rofecoxib) on the Recurrence of Colorectal Adenomas (0966-122)
Status: Completed Condition: Colorectal Adenoma

A Study of Rofecoxib in the Treatment of Post-Operative Pain After Total Knee Joint Replacement (0966-259)
Status: Terminated Condition: Pain

Treatment With MK0966 for the Prevention of Prostate Cancer (0966-201)
Status: Completed Condition: Prostate Cancer

A Study to Evaluate Rofecoxib Versus Placebo and Diclofenac in Patients With Acute Painful Rotator Cuff Syndrome
Status: Terminated Condition: Pain

Safety of Lumiracoxib in Patients With Osteoarthritis
Status: Completed Condition: Osteoarthritis

Barrett's Esophagus - 315 - 3 Way Cross Over
Status: Completed Condition: Barrett's Esophagus

GECO: Study of Rofecoxib and Prolonged Constant Infusion of Gemcitabine in the Polychemotherapy Treatment of Advanced Non-Small Cell Lung Cancer
Status: Completed Condition: Advanced Non-Small Cell Lung Cancer

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck
VIOXX
rofecoxib
SUSPENSION;ORAL021052May 20, 1999DISCNNo5,474,995*PED<disabled><disabled>
Merck
VIOXX
rofecoxib
SUSPENSION;ORAL021052May 20, 1999DISCNNo5,691,374*PED<disabled>Y<disabled>
Merck
VIOXX
rofecoxib
SUSPENSION;ORAL021052May 20, 1999DISCNNo6,063,811*PED<disabled>Y<disabled>
Merck
VIOXX
rofecoxib
SUSPENSION;ORAL021052May 20, 1999DISCNNo6,239,173*PED<disabled><disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc